PROPORTIONAL PROINSULIN RESPONSES IN 1ST-DEGREE RELATIVES OF PATIENTS WITH TYPE-2 DIABETES-MELLITUS

被引:14
|
作者
RODER, ME
ERIKSSON, J
HARTLING, SG
GROOP, L
BINDER, C
机构
[1] STENO DIABET CTR,GENTOFTE,DENMARK
[2] HELSINKI UNIV HOSP,DEPT MED 4,HELSINKI,FINLAND
关键词
C-PEPTIDE; DIABETES MELLITUS; GLUCOSE CLAMP; INSULIN; PROINSULIN;
D O I
10.1007/BF00572856
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Elevated fasting proinsulin immunoreactive material (PIM) has previously been found in patients with type 2 (non-insulin-dependent) diabetes mellitus. It is not known whether this is a genetic trait or whether it is related to the manifestation of type 2 diabetes. Neither is it clear whether the raised fasting insulin immunoreactivity previously observed in first-degree relatives of patients with type 2 diabetes is due to raised PIM. Furthermore, it has not been investigated whether first-degree relatives have altered PIM responses to different secretagogoues. To study this, PIM, insulin and C-peptide were measured in patients with type 2 diabetes, in their first-degree relatives and in healthy control subjects in the fasting state and in relatives and controls during a hyperglycemic clamp. At the end of the hyperglycemic clamp, 0.5 mg of glucagon was given intravenously to stress the beta cells further. Fasting PIM concentrations were significantly higher in patients with type 2 diabetes (P < 0.05). These patients did not have significantly elevated fasting insulin levels when corrected for PIM. In the relatives, fasting insulin concentrations were elevated but PIM levels were normal suggesting that the increase in fasting insulin concentrations reflected an increase in true insulin. The incremental PIM, insulin and C-peptide responses to glucose and glucagon in the relatives were not different from those in the controls. We conclude that elevated fasting PIM levels in patients with type 2 diabetes seem not to be a genetic trait. First-degree relatives of patients with type 2 diabetes are truly hyperinsulinemic in the fasting state, and they have proportional PIM, insulin and C-peptide responses to glucose and glucagon.
引用
收藏
页码:132 / 137
页数:6
相关论文
共 50 条
  • [31] INSULIN RELEASE IN TYPE-2 DIABETES-MELLITUS
    EFENDIC, S
    KHAN, A
    OSTENSON, CG
    DIABETES & METABOLISM, 1994, 20 (02): : 81 - 86
  • [32] PANCREATIC ABNORMALITIES IN TYPE-2 DIABETES-MELLITUS
    不详
    LANCET, 1987, 2 (8574): : 1497 - 1498
  • [33] THE CHIARI TYPE-I MALFORMATION IN 2 MONOZYGOTIC TWINS AND 1ST-DEGREE RELATIVES
    STOVNER, LJ
    CAPPELEN, J
    NILSEN, G
    SJAASTAD, O
    ANNALS OF NEUROLOGY, 1992, 31 (02) : 220 - 222
  • [34] A 25-YEAR FOLLOW-UP-STUDY OF GLUCOSE-TOLERANCE IN 1ST-DEGREE RELATIVES OF TYPE-2 DIABETIC-PATIENTS
    ERPENSTEIN, A
    NAUCK, M
    WIRTZ, G
    VANBOXBERG, C
    TILLIL, H
    ARMSTRONG, V
    KOBBERLING, J
    CREUTZFELDT, W
    DIABETOLOGIA, 1993, 36 : A73 - A73
  • [35] THYROID AUTOANTIBODIES IN BLACK AND IN WHITE-CHILDREN AND ADOLESCENTS WITH TYPE-1 DIABETES-MELLITUS AND THEIR 1ST DEGREE RELATIVES
    BUREK, CL
    ROSE, NR
    GUIRE, KE
    HOFFMAN, WH
    AUTOIMMUNITY, 1990, 7 (2-3) : 157 - 167
  • [36] ENDOTHELIN-1 DOES NOT CAUSE VASOCONSTRICTION IN PATIENTS WITH TYPE-2 DIABETES-MELLITUS
    NUGENT, AG
    MCGURK, C
    HAYES, JR
    JOHNSTON, GD
    DIABETOLOGIA, 1995, 38 : A48 - A48
  • [37] PITTED ENAMEL HYPOPLASIA IN TUBEROUS SCLEROSIS PATIENTS AND 1ST-DEGREE RELATIVES
    LYGIDAKIS, NA
    LINDENBAUM, RH
    CLINICAL GENETICS, 1987, 32 (04) : 216 - 221
  • [38] EXPRESSION OF AN INTERSPECIES IDIOTYPE IN SERA OF SLE PATIENTS AND THEIR 1ST-DEGREE RELATIVES
    DANG, H
    TAKEI, M
    ISENBERG, D
    SHOENFELD, Y
    BACKIMER, R
    RAUCH, J
    TALAL, N
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1988, 71 (03): : 445 - 450
  • [39] LEUKOCYTE CHEMOTAXIS IN DIABETIC-PATIENTS AND THEIR NONDIABETIC 1ST-DEGREE RELATIVES
    MOLENAAR, DM
    PALUMBO, PJ
    WILSON, WR
    RITTS, RE
    DIABETES, 1976, 25 : 880 - 883
  • [40] HYPOGLYCEMIA AND CARDIAC-ARRHYTHMIAS IN PATIENTS WITH TYPE-2 DIABETES-MELLITUS
    LINDSTROM, T
    JORFELDT, L
    TEGLER, L
    ARNQVIST, HJ
    DIABETIC MEDICINE, 1992, 9 (06) : 536 - 541